全球卫生治理下的《与贸易相关的知识产权协定》中弹性条款与药品可及性问题研究

发布时间：2018-04-22 10:17

  本文选题：TRIPS协议 + 弹性条款　； 参考：《中国新药杂志》2017年09期

【摘要】：在全球卫生治理中,如何平衡药品研发技术创新与药品可及性之间的问题由来已久,发达国家和发展中国家在这一议题上的利益界定与谈判策略分歧也逐渐加大。本文通过分析弹性条款以及发达国家与发展中国家持有不同立场,认为中国在参与全球卫生治理中,充分使用《与贸易相关的知识产权协定》(TRIPS协议)下的弹性条款,维护发展中国家的利益,是必要的选择。
[Abstract]:In global health governance, the problem of how to balance the technological innovation of drug research and development and the availability of drugs has a long history, and the differences of interest definition and negotiation strategies between developed and developing countries on this issue have gradually increased. Based on the analysis of flexible clauses and the differences between developed countries and developing countries, this paper holds that China makes full use of the flexible clauses under trips in its participation in global health governance. Safeguarding the interests of developing countries is a necessary choice.
【作者单位】： 北京大学医学人文研究院;北京大学公共卫生学院全球卫生系;
【分类号】：D997.1
，

本文编号：1786776